Association of human cytomegalovirus in urine with end-organ diseases in stage 2/3 HIV-1-infected individuals

Zhao, Fang1; Chen, Zhiwei3,4; Wang, Hui1; Cheung, Allen Ka Loon2,5

2023

10.1016/j.jcv.2022.105351

JOURNAL OF CLINICAL VIROLOGY   影响因子和分区

1386-6532

1873-5967

Background: Human cytomegalovirus (HCMV) is prevalent in human immunodeficiency virus type 1 (HIV-1) -infected individuals but is suppressed by the host immune system bolstered by antiretroviral therapy. During stage 4 of HIV-1 infection, HCMV becomes a major risk factor for end-organ diseases (EODs). However, the implications of detecting HCMV in patients with stage 2/3 HIV-1 infection have not been established.Objectives: Conduct a retrospective study of the relationship between HCMV-DNA detection and EODs in patients with stage 2/3 HIV-1 infection.Study design: We cross-sectionally analyzed data from 134,881 HIV-1-infected patients who visited the Third People's Hospital of Shenzhen (Guangdong, China) between January 2011 and June 2022. Only patients with available data on CD4 counts, HIV-RNA and HCMV-DNA copy numbers, and hospitalized stage 2/3 patients with detailed clinical assessments of EODs were included in this study. The chi-square test and Cox regression model were used to examine the association between HCMV-DNA detection and EOD incidence. Longitudinal analysis was performed to examine the effect of anti-HCMV treatment on the incidence of lung and cardiovascular EODs.Results: HCMV-DNA had been tested in the blood and urine of 98.6% and 31.8% of the HIV-1-infected patients, respectively. An increased percentage of HCMV was detected in urine (> 2.4-fold) than in blood at different HIV -1 infection stages. In stage 2/3 patients (n = 454), a higher incidence of EODs was observed in those who tested positive for HCMV-DNA in urine (P < 0.0001) than in those who tested positive for HCMV-DNA in blood (P = 0.0977). Using a model for incidence of EODs, we found that HCMV-DNA detection in urine was associated with an increased incidence of lung EOD; the adjusted hazard ratio (HR) was 1.939 (95% confidence interval [CI]: 1.326-2.761, P = 0.0003) for the HCMVurine+ subgroup and 0.933 (95% CI: 0.523-1.623, P = 0.8605) for the HCMVurine-subgroup. A significant HR was also observed for cardiovascular EOD, which was 0.696 (95% CI: 0.492-0.953, P = 0.0302) for the HCMVurine+ group and 1.56 (95% CI: 0.766-3.074, P = 0.2033) for the HCMVurine-group. Longitudinal analysis showed that treatment for HCMV reduced the incidence rates of lung and cardiovascular EODs in the stage 2/3 patients.Conclusions: The presence of HCMV in urine is associated with the early prognosis of EODs in patients with stage 2/3 HIV-1 infection and its detection should be implemented as a routine test.

Human cytomegalovirus HIV-1 stage 2 3 End -organ diseases HCMV-DNA detection HIV-1

SCI

英语

第一 ; 通讯

[18170032] ; [T12-712/21-R] ; [SZSM201512029] ; [T11-706/18-N] ; [2018ZX10731101-002-001]

Virology

Virology

WOS:000906217200001

ELSEVIER

MICROBIOLOGY

Web of Science

1.Southern Univ Sci & Technol, Peoples Hosp Shenzhen 3, Natl Clin Ctr Infect Dis, Dept Infect Dis,Affiliated Hosp 2, Shenzhen, Guangdong, Peoples R China
2.Hong Kong Baptist Univ, Fac Sci, Dept Biol, Kowloon Tong, Hong Kong, Peoples R China
3.Univ Hong Kong, AIDS Inst, LKS Fac Med, Pokfulam, Peoples R China
4.Univ Hong Kong, LKS Fac Med, Dept Microbiol, Pokfulam, Peoples R China
5.Hong Kong Baptist Univ, Fac Sci, Dept Biol, Kowloon Tong, Hong Kong, Peoples R China

Zhao, Fang,Chen, Zhiwei,Wang, Hui,et al. Association of human cytomegalovirus in urine with end-organ diseases in stage 2/3 HIV-1-infected individuals[J]. JOURNAL OF CLINICAL VIROLOGY,2023,158.

Zhao, Fang,Chen, Zhiwei,Wang, Hui,&Cheung, Allen Ka Loon.(2023).Association of human cytomegalovirus in urine with end-organ diseases in stage 2/3 HIV-1-infected individuals.JOURNAL OF CLINICAL VIROLOGY,158.

Zhao, Fang,et al."Association of human cytomegalovirus in urine with end-organ diseases in stage 2/3 HIV-1-infected individuals".JOURNAL OF CLINICAL VIROLOGY 158(2023).